Abbott
No, it's not easy, but if Grace Groner -- a secretary for 43 years -- could pull off the even more astonishing feat of amassing a $7 million fortune, then it is within the realm of possibility. In fact, Groner's strategy is about the only one with a shot at success. Read on to find out what she did.
DailyFinance's Top 11 Value Stocks for 2011
6:45AM 12/30/2010
Investing, Intel, Stock Picks, Abbott, Chevron, DuPont, Market News
Wall Street's consensus sees the S&P 500 tacking on an 11% gain over the next 12 months -- with lots of ups and downs along the way. That has us inclined to play defense, with an eye toward bargain stocks paying generous, sustainable dividends. Here are our top 11 picks for 2011.
The Top 10 Health Care Stories of 2010
7:30AM 12/29/2010
Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Abbott, Astrazeneca
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our rundown of the biggest health care stories.
Abbott Laboratories Recalls 359 Million Diabetes Test Strips
7:15PM 12/22/2010
Abbott Laboratories is recalling roughly 359 million blood-sugar test strips for diabetics after the strips turned out to yield falsely low readings.
Merck KGaA Is Latest Pharma to Settle Justice Department Claims
2:00PM 12/21/2010
Health Care, Pfizer, Merck, GlaxoSmithKline, Abbott, Eli Lilly
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.
Arena Shares Finish Higher After FDA Rejects Obesity Drug Lorcaserin
4:00PM 10/25/2010
Arena Pharmaceuticals announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the potential risks outweigh the minimal efficacy.
Inside Wall Street: Biotechs vs. Big Pharma in a Swedish Showdown
7:30AM 10/18/2010
Company News, Columns, Investing, Health Care, Pfizer, Bristol-Myers Squibb, Abbott, Stocks in the News
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off.
Abbott Pulls Weight Loss Drug Meridia from the Market
4:14PM 10/08/2010
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
Abbott has recalled 5 million containers of its top-selling powdered baby formula, Similac, after finding beetles at one of its factories. But parents shouldn't panic, the company says. The chances that any beetlejuice actually made it into the formula is slim, and doctors say babies wouldn't be harmed even if it did.
Abbott to Layoff 3,000 Employees Following Solvay Unit Acquisition
12:10PM 9/21/2010
Giant U.S. pharmaceutical group Abbott Laboratories is cutting 3,000 jobs, or about 3% of its workforce, following its purchase of Belgian-based Solvay's drugs business.
More Stories
Next Page →
Most Popular Stories
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Why Your 2012 Tax Bill May Jump By $8,000
Savings Experiment: Tissues vs. Toilet Paper
Savings Experiment: Snow Removal
Why the U.S. Should Get Rid of the $1 BillDailyFinance Wire
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
- Tax Time for Single Parents Can Be Doubly Aggravating
Newswire
- Greek deal to cut spending does not end debt...
- $25B settlement reached over foreclosure abuses
- Stocks close higher after debt deal in Greece
- Euro ministers cautious on Greek bailout deal
- LinkedIn's 4Q earnings strong, revenue doubles
- 2 Key leaders in Ford's renaissance will retire
- Kodak to stop making cameras, digital frames
- Pepsico to cut 8,700 jobs; 4Q net rises
- LinkedIn 2012 Outlook: EBITDA vs. EPS (LNKD)
- 24/7 Wall St. Closing Bell (AONE, EXPE, RIMM, AMGN, MMM, AAPL, CSCO, AMSC, BG, DNKN, LO, PEP, PM, SIRI, TDC, IPSU, TSL, DMND, GRPN, TLEO, CZR)
- More Short Covering Exaggerates Solar Rallies (TAN, FSLR, SPWR, ENER, TSL, WFR)
- The Case For and Against SIRIUS XM… Value Versus Pandora? (SIRI, P)
- Mid-day Movers (IPSU, DMND, TSL, ARRY, AONE)
- Apple Captures 80% of Mobile Phone Company Profits (AAPL, SSNLF, RIMM, NOK, MMI, GOOG, MSFT)
- Meet the New Scaled Down Eastman Kodak (EKDKQ)
- After Taleo, Looking at Other Cloud M&A ‘Hopefuls’ (SKYY, TLEO, ORCL, EQIX, AKAM, RAX, TDC, NTAP, CRM)
Follow Us
